Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

HLA-DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD

Maximilian Alexander Rohnert, Jonas Schadt, Michael Kramer, Christoph Röllig, Johannes Schetelig, Friedrich Stölzel, Désirée Kunadt, Jan Moritz Middeke, Lars Thielecke, Friedemann Uschner, Ingmar Glauche, Christian Thiede, Martin Bornhaeuser, Uta Oelschlaegel, Malte von Bonin, Uwe Platzbecker, Claudia D Baldus, Hubert Serve, Carsten Mueller-Tidow

Blood (2024) 144 (Supplement 1): 2948.

https://doi.org/10.1182/blood-2024-194874

Published: 2024

Journal Articles

Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis

Blood (2022) 140 (Supplement 1): 3317–3319.

https://doi.org/10.1182/blood-2022-167677

Published: 2022

Journal Articles

Fast-Track Measurable Residual Disease Detection By Multiparametric Flow Cytometry in Acute Myeloid Leukemia before Allogeneic Hematopoietic Cell Transplantation

Maximilian Alexander Röhnert, Michael Kramer, Jonas Schadt, Philipp Ensel, Christoph Röllig, Johannes Schetelig, Friedrich Stölzel, Martin Bornhaeuser, Uta Oelschlägel, Malte von Bonin

Blood (2022) 140 (Supplement 1): 11824–11826.

https://doi.org/10.1182/blood-2022-165260

Published: 2022

Journal Articles

Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Blood (2022) 140 (Supplement 1): 523–525.

https://doi.org/10.1182/blood-2022-157126

Published: 2022

Journal Articles

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

Blood (2022) 140 (Supplement 1): 3327–3328.

https://doi.org/10.1182/blood-2022-159897

Published: 2022

Journal Articles

CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

Blood (2022) 139 (1): 87–103.

https://doi.org/10.1182/blood.2020009680

Published: 2022

Includes: Supplemental data

Journal Articles

Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries

Blood (2021) 138 (Supplement 1): 872.

https://doi.org/10.1182/blood-2021-147735

Published: 2021

Journal Articles

Intensified Cytarabine Dose during Consolidation Therapy in AML Patients Under 65 Years Is Not Associated with Survival Benefit

Blood (2021) 138 (Supplement 1): 1242.

https://doi.org/10.1182/blood-2021-146606

Published: 2021

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Blood (2021) 138 (Supplement 1): 173.

https://doi.org/10.1182/blood-2021-145167

Published: 2021

Journal Articles

Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study

Blood (2021) 138 (Supplement 1): 4418.

https://doi.org/10.1182/blood-2021-151287

Published: 2021

Journal Articles

Prediction of Complete Remission and Survival in Acute Myeloid Leukemia Using Supervised Machine Learning

Blood (2021) 138 (Supplement 1): 108.

https://doi.org/10.1182/blood-2021-149582

Published: 2021

Journal Articles

Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience

Blood (2021) 138 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2021-145917

Published: 2021

Journal Articles

Transcriptomic Features of Immune Exhaustion and Senescence Predict Outcomes and Define Checkpoint Blockade-Unresponsive Microenvironments in Acute Myeloid Leukemia

Sergio Rutella, Jayakumar Vadakekolathu, Francesco Mazziotta, Stephen Reeder, Tung On Yau, Rupkatha Mukhopadhyay, Heidi Altmann, Michael Kramer, Hanna A. Knaus, Joshua F. Zeidner, Vedran Radojcic, Andrea Arruda, Mark D. Minden, Sarah K Tasian, Martin Bornhäuser, Ivana Gojo, Leo Luznik

Blood (2021) 138 (Supplement 1): 223.

https://doi.org/10.1182/blood-2021-145854

Published: 2021

Journal Articles

Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up

Maximilian Alexander A Rohnert, Malte von Bonin, Michael Kramer, Philipp Ensel, Nadja Holtschke, Christoph Rollig, MD MSC, Martin Bornhäuser, MD, Veit Buecklein, MD, Marion Subklewe, MD, Stefan W Krause, Simon Voelkl, Tobias Berg, Michael A Rieger, Cornelia Brendel, Jörg Hoffmann, Nicole Hofmeister-Mielke, Richard F. Schlenk, Sylvie D Freeman, Uta Oelschlägel

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-138683

Published: 2020

Journal Articles

Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-138427

Published: 2020

Journal Articles

Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial

Blood (2020) 136 (Supplement 1): 1–3.

https://doi.org/10.1182/blood-2020-140246

Published: 2020

Journal Articles

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Blood (2020) 136 (7): 823–830.

https://doi.org/10.1182/blood.2019004583

Published: 2020

Includes: Supplemental data

Journal Articles

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Christoph Röllig, MD MSC, Michael Kramer, M.Sc., Christoph Schliemann, Jan-Henrik Mikesch, MD, Björn Steffen, MD, Alwin Krämer, MD, Tim Sauer, MD, Mathias Hänel, MD, Regina Herbst, MD, Kerstin Schäfer-Eckart, MD, Richard Noppeney, MD, Edgar Jost, MD, Tim H Brümmendorf, MD, Stefan W Krause, MD, Volker Kunzmann, MD PhD, Hermann Einsele, MD, Sebastian Scholl, Andreas Hochhaus, MD, Lars R. Fransecky, MD, Martin Kaufmann, MD, Andreas Neubauer, MD, Dirk Niemann, MD, Markus Schaich, MD, Norbert Frickhofen, MD, Alexander Kiani, Frank Heits, MD, Ulrich Krümpelmann, Ulrich Kaiser, MD, Johannes Kullmer, Maxi Wass, MD, Stefan Klein, MD, Malte Von Bonin, Jan Moritz Middeke, MD, Christian Thiede, MD, Friedrich Stoelzel, MD, Johannes Schetelig, MDMSc, Gerhard Ehninger, MD, Claudia D Baldus, Carsten Müller-Tidow, MD, Uwe Platzbecker, Hubert Serve, MD, Martin Bornhäuser, MD

Blood (2019) 134 (Supplement_1): 13.

https://doi.org/10.1182/blood-2019-123717

Published: 2019

Journal Articles

Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3 -ITD: Results from an International Collaboration

Sabine Kayser, MD, Michelle A Elliott, MD, Marlise Luskin, MDMS, Andrew M. Brunner, MD, Michael Kramer, M.Sc., Zdenek Racil, MD, Zuzana Sustkova, MD, Petr Cetkovsky, MD MBA, PhD, Jan Novak, MD PhD, Friedrich Stoelzel, MD, Christian Thiede, MD, Carsten Müller-Tidow, MD, Uwe Platzbecker, Christoph Röllig, MD MSC, Richard F. Schlenk, MD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 2693.

https://doi.org/10.1182/blood-2019-125317

Published: 2019

Journal Articles

Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZA2 Trial

Blood (2019) 134 (Supplement_1): 644.

https://doi.org/10.1182/blood-2019-129926

Published: 2019

NARROW

HLA-DR Expression on Leukemic Progenitor Cells before Allogeneic Hematopoietic Cell Transplantation Adds Prognostic Value in the Presence of MRD

Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment: A Propensity Score Matching Analysis

Fast-Track Measurable Residual Disease Detection By Multiparametric Flow Cytometry in Acute Myeloid Leukemia before Allogeneic Hematopoietic Cell Transplantation

Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial

Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from Dataml, SAL and Pethema European Registries

Intensified Cytarabine Dose during Consolidation Therapy in AML Patients Under 65 Years Is Not Associated with Survival Benefit

Allogeneic Hematopoietic Cell Transplantation in Patients ≤ 60 Years with Intermediate-Risk Acute Myeloid Leukemia in First Remission - Results of the Randomized Etal-1 Trial-

Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study

Prediction of Complete Remission and Survival in Acute Myeloid Leukemia Using Supervised Machine Learning

Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy: A Real-World Registry Experience

Transcriptomic Features of Immune Exhaustion and Senescence Predict Outcomes and Define Checkpoint Blockade-Unresponsive Microenvironments in Acute Myeloid Leukemia

Identification of Prognostic Immunophenotypes at First Diagnosis in Patients with Acute Myeloid Leukemia (AML) By a Standardized Multicolor Flow Cytometry (MFC) Panel Originally Designed to Detect Measurable Residual Disease (MRD) at Follow-up

Impact of Genetic Abnormalities and Measurable Residual Disease Levels on Outcome in Patients with MDS/AML Pre-Emptively Treated with Azacitidine: Correlative Results of the Prospective RELAZA2 Trial

Remission and Survival after Single Versus Double Induction with 7+3 for Newly Diagnosed Acute Myeloid Leukemia: Results from the Planned Interim Analysis of Randomized Controlled SAL-Daunodouble Trial

Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia?

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3 -ITD: Results from an International Collaboration

Azacitidine for Pre-Emptive Treatment of Measurable-Residual Disease in MDS/AML Patients at High Risk of Hematological Relapse: Results of the Second Cohort of the RELAZA2 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only